Journal of Cystic Fibrosis
Volume 8, Issue 5 , Pages 295-315 , September 2009

Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus

  • Harry Heijerman

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +31 702100000; fax: +31 702102150.
    • ,
  • Elsbeth Westerman
    • ,
  • Steven Conway
    • ,
  • Daan Touw
    • ,
  • Gerd Döring for the consensus working group

      Affiliations

    • Baroukh Assael, Cystic Fibrosis Center, Verona, Italy; Ian Balfour-Lynn, Royal Brompton & Harefield NHS Trust, Sydney Street, London, United Kingdom; Gabriel Bellon, Hôpital Debrousse, Lyon, France; Celeste Barreto, Hospital de Santa Maria, Lisbon, Portugal; Cesare Braggion, Ospedale Civile Maggiore, Verona, Italy; Steven Conway, St James University Hospital, Leeds, UK; Christiane De Boeck, University Hospital Gasthuiberg, Leuven, Belgium; Gerd Döring, Institute of Medical Microbiology and Hygiene, Eberhard-Karls-Universität, Tübingen, Germany; Jean-Christophe Dubus, Faculté de Médecine, Marseille, France; Irmgard Eichler, EMEA, London; Mark Elkins, Royal Prince Alfred Hospital, Sydney Australia; Henderik Frijlink, University of Groningen, Groningen, The Netherlands; Charles Gallagher, St Vincent's Hospital, Dublin, Ireland; Silvia Gartner, University Hospital Vall d'Hebron, Barcelona, Spain; David Geller, Nemours Children's Clinic, Orlando, USA; Matthias Griese, University of Munich, Munich, Germany; Harry Heijerman, Haga Teaching Hospital, The Hague, The Netherlands; Lena Hjelte, Karolinska University Hospital Huddinge, Stockholm, Sweden; Margaret Hodson, Royal Brompton Hospital, London, United Kingdom; Niels Høiby, Rigshospitalet, Copenhagen, Denmark; James Littlewood, St. James's University Hospital, Leeds, UK; Anne Malfroot, Academisch Ziekenhuis, Vrije Universiteit Brussel, Brussels, Belgium; Alexander Möller, University Children's Hospital, Zurich, Switzerland; Petr Pohunek, Charles University 2nd Medical School, Prague, Czech Republic; Tanja Pressler, Rigshospitalet, Copenhagen, Denmark; Alexandra Quittner, University of Miami, Miami, USA; Felix Ratjen, Hospital for Sick Children, Toronto, Canada; Martin Schöni, University of Berne, Berne, Switzerland; Giovanni Taccetti, Ospedale Meyer, Florence, Italy; Harm Tiddens, Erasmus University Medical Center, Rotterdam, The Netherlands; Daan Touw, Apotheek Haagse Ziekenhuizen, The Hague, The Netherlands; Elsbeth Westerman, Apotheek Haagse Ziekenhuizen, The Hague, The Netherlands.

Received 31 January 2009 ,Revised 5 April 2009 ,Accepted 8 April 2009.

References 

  1. Cystic Fibrosis Foundation . In: Cystic Fibrosis Foundation Patient Registry 2005 Annual Data Report. Bethesda: Cystic Fibrosis Foundation; 2006;
  2. In:  Hodson ME,  Geddes D,  Bush A editor. Cystic fibrosis. 3rd ed. London: Hodder Arnold; 2007;Part 2
  3. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell. 1998;95:1005–1010
  4. Ratjen F, Döring G. Cystic fibrosis. Lancet. 2003;361:681–689
  5. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Gutièrrez JP, Hull J, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med. 1997;156:1197–1204
  6. Stern M, Sens B, Wiedemann B, Busse O. Qualitätssicherung Mukoviszidose - Überblick über den Gesundheitszustand der Patienten in Deutschland 2001. Eds, Zentrum für Qualitätsmanagement im Gesundheitswesen. Ärztekammer Hannover, 2002.
  7. Govan JRW, Glass S. The microbiology and therapy of cystic fibrosis lung infections. Rev Med Microbiol. 1990;1:19–28
  8. van Schilfgaarde M, Eijk P, Regelink A, et al. Haemophilus influenzae localized in epithelial cell layers is shielded from antibiotics and antibody-mediated bactericidal activity. Microb Pathog. 1999;26:249–262
  9. Liou TG, Adler FR, FitzSimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001;153:345–352
  10. Döring G, Hoiby N for the Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros. 2004;3:67–91
  11. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Bruce KD. Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol. 2004;42:5176–5183
  12. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Kehagia V, et al. Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis. J Clin Microbiol. 2006;44:2601–2604
  13. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis. 1990;141:914–921
  14. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999;340:23–30
  15. Hoiby N, Frederiksen B. Microbiology of cystic fibrosis. In:  Hodson ME,  Geddes D editor. Cystic fibrosis. London: Arnold; 2000;p. 83–108
  16. Kosorok MR, Zeng L, West SE, Rock MJ, Splaingard ML, Collins J, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol. 2001;32:277–287
  17. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest. 2002;109:317–325
  18. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947–2003. Eur Respir J. 2007;29:522–526
  19. Smith AL, Ramsey BW, Hedges DL, Hack B, Williams-Warren J, Weber A, et al. Safely of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol. 1989;7:265–271
  20. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science. 2000;288:1251–1254
  21. Hogardt M, Schmoldt S, Henke C, Bader L, Heesemann J. Stage-specific adaptation of hypermutable Pseudomonas aeruginosa isolates during chronic pulmonary infection in patients with cystic fibrosis. J Infect Dis. 2007;195:70–80
  22. Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonization in cystic fibrosis by early treatment. Lancet. 1991;338:725–726
  23. Wiesemann HG, Steinkamp G, Ratjen F, Bauernfeind A, Przyklenk B, Döring G, et al. Placebo controlled, double blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in patients with cystic fibrosis. Pediatr Pulmonol. 1998;25:88–92
  24. Ratjen F, Döring G, Nikolaizik W. Eradication of Pseudomonas aeruginosa with inhaled tobramycin in patients with cystic fibrosis. Lancet. 2001;358:983–984
  25. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med. 2003;167:841–849
  26. Taccetti G, Campana S, Festini F, Mascherini M, Döring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J. 2005;26:1–4
  27. Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol. 2007;42:610–623
  28. Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med. 1994;150:448–454
  29. Döring G, Ratjen F. Immunology of cystic fibrosis. In:  Fibrosis Cystic,  Hodson ME,  Geddes D,  Bush A editor. London: Arnold Hammer; 2007;p. 69–80
  30. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995;332:848–854
  31. Konstan MW, Schluchter MD, Xue W, Davis PB. Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med. 2007;176:1084–1089
  32. Birke FW, Meade CJ, Anderskewitz R, Speck GA, Jennewein HM. In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist. J Pharmacol Exp Ther. 2001;297:458–466
  33. Griese M, Kappler M, Gaggar A, Hartl D. Inhibition of airway proteases in cystic fibrosis lung disease. Eur Respir J. 2008;32:783–795
  34. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax. 2002;57:212–216
  35. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomized, placebo-controlled crossover trial. Lancet. 2002;360:978–984
  36. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290:1749–1756
  37. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994;331:637–642
  38. Frederiksen B, Pressler T, Hansen A, Koch C, Høiby N. Effect of aerosolized rhDNase (Pulmozyme®) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatr. 2006;95:1070–1074
  39. Robinson M, Hemming AL, Regnis JA, Wong AG, Bailey DL, Bautovich GJ, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax. 1997;52:900–903
  40. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354:229–240
  41. Döring G, Conway SP, Heijerman HG, Hodson ME, Høiby N, Smyth A, et al. for the Consensus Committee Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J. 2000;16:749–767
  42. Park MK, Myers RA, Marzella L. Oxygen tensions and infections: modulation of microbial growth, activity of antimicrobial agents, and immunologic responses. Clin Infect Dis. 1992;14:720–740
  43. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med. 1993;328:1740–1746
  44. Moss RB. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest. 2001;120(3 Suppl):107S–113S
  45. Moss RB. Long-term benefits of inhaled tobramycin in adolescents with cystic fibrosis. Chest. 2002;121:55–63
  46. Murphy TD, Anbar RD, Lester LA, Nasr SZ, Nickerson B, VanDevanter DR, et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol. 2004;38:314–320
  47. Nikolaizik WH, Trociewicz K, Ratjen F. Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis. Eur Respir J. 2002;20:122–126
  48. Ho BL, Ho SL, Dupuis A, Corey M, Coates AL. Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin. Chest. 2002;122:930–934
  49. Jensen T, Pedersen SS, Garne S, Heilmann C, Høiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother. 1987;19:831–838
  50. Hodson ME, Gallagher CG, Govan JRW. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J. 2002;20:658–664
  51. Adeboyeku D, Scott S, Hodson ME. Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis. J Cyst Fibros. 2006;5:261–263
  52. Frederiksen B, Koch C, Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol. 1997;23:330–335
  53. Alothman GA, Ho B, Alsaadi MM, Ho SL, O'Drowsky L, Louca E, et al. Bronchial constriction and inhaled colistin in cystic fibrosis. Chest. 2005;127:522–529
  54. Cunningham S, Prasad A, Collyer L, Carr S, Balfour-Lynn IM, Wallis C. Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch Dis Child. 2001;84:432–433
  55. Westerman EM, Le Brun PP, Touw DJ, Frijlink HW, Heijerman HG. Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J Cyst Fibros. 2004;3:23–28
  56. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008;178:921–928
  57. Keller M, Stempfle P, Reul K, Waldner R, Lintz FC, Opolski S. High efficiency pulmonary drug delivery of a novel formulation of aztreonam by the eFlow™. Poster 030. In: Congress of the International Society for Aerosols in Medicine. Baltimore. 2003;
  58. Gibson RL, Retsch-Bogart GZ, Oermann C, Milla C, Pilewski J, Daines C, et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol. 2006;41:656–665
  59. Retsch-Bogart GZ, Burns JL, Otto KL, Liou TG, McCoy K, Oermann C, et al. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol. 2008;43:47–58
  60. Retsch-Bogart GZ, Quittner A, Montgomery AB, Gibson R, McCoy K, Oermann C, et al. Phase 3 trial (AIR-CF1) measuring improvement in respiratory symptoms in patients with cystic fibrosis (CF) following treatment with aztreonam lysine for inhalation (AZLI). Pediatr Pulmonol. 2007;42(S30):310
  61. Fitzgeorge RB, Baskerville A, Featherstone AS. Treatment of experimental Legionnaires disease by aerosol administration of rifampicin, ciprofloxacin, and erythromycin. Lancet. 1986;8479:502–503
  62. Conley J, Yang H, Wilson T, Blasetti K, Di Ninno V, Schnell G, et al. Ciprofloxacin: aerosol characterisation and efficacy against Francisella tularensis infection in mice. Antimicrob Agents Chemother. 1997;41:1288–1292
  63. Griffith DC, Rock J, Hansen C, Pressler T, Balden T, Jensen TJ, et al. Pharmacokinetics and safety of MP-376 (levofloxacin solution for inhalation) in normal healthy volunteers and cystic fibrosis patients. Pediatr Pulmonol. 2007;42(S30):303
  64. Allen SD, Sorenson KN, Nejdl MJ, Durrant C, Proffit RT. Prophylactic efficacy of aerosolised liposomal (AmBisone) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother. 1994;34:1001–1013
  65. Knechtel SA, Klepser ME. Safety of aerosolised amphotericin B. Expert Opin Drug Saf. 2007;6:523–532
  66. Ruiz I, Molina I, Gavalda J, Bueno J, Barrenetxea C, Zuazu J, et al. Safety and tolerability of nebulised liposomal Amphotericin B in haematologic patients. In: 45th Interscience Conference on antimicrobial agents and chemotherapy. 2005;Poster M-977
  67. Lowry CM, Marty FM, Vargas SO, Lee JT, Fiumara K, Deykin A, et al. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. Transpl Infect Dis. 2007;9:121–125
  68. Mohammed RA, Klein KC. Inhaled amphotericin B for prophylaxis against invasive Aspergillus infections. Ann Pharmacother. 2006;40:2148–2154
  69. Tiddens HA, Pfaff SJ, van der Zanden T, Ruijgrok EJ. Weekly nebulisation of liposomal amphotericine B for the treatment of prednisone dependent ABPA. Pediatr Pulmonol. 2003;36(S25):301
  70. Sanchez-Sousa A, Alvarez ME, Maiz L, Escobar H, Sadaba B, Suarez L, et al. Control of Aspergillus bronchial colonization in cystic fibrosis patients: preliminary data using AmBisone aerosol therapy. In: XIIIth International Cystic Fibrosis Congress. 1996;p. S256
  71. McCoy K, Hamilton S, Johnson C. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Chest. 1996;110:889–895
  72. Quan JM, Tiddens HAWM, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr. 2001;139:813–820
  73. Robinson TE, Goris ML, Zhu HJ, Chen X, Bhise P, Sheikh F, et al. Dornase alfa reduces air trapping in children with mild cystic fibrosis. Chest. 2005;128:2327–2335
  74. Jones AP, Wallis CE. Recombinant human deoxyribonuclease for cystic fibrosis (Cochrane Review). In: The Cochrane Library. Oxford: Update Software; 2003;Issue 3
  75. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006;354:241–250
  76. Wark PA, McDonald V, Jones AP. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev. 2005;(3):Art No: CD001506.pub2
  77. Eng PA, Morton J, Douglass JA, Riedler J, Wilson J, Robertson CF. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol. 1996;21:77–83
  78. Suri R, Metcalfe C, Lees B, Grieve R, Flather M, Normand C, et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet. 2001;358:1316–1321
  79. Ballmann M, von der Hardt H. Hypertonic saline and recombinant human DNase: a randomised crossover pilot study in patients with cystic fibrosis. J Cyst Fibros. 2002;1:35–37
  80. Kellerman D, Rossi Mospan A, Engels J, Schaberg A, Gorden J, Smiley L. Denufosol: a review of studies with inhaled P2Y2 agonists that led to Phase 3. Pulm Pharmacol Ther. 2008;21:600–607
  81. Drutz D, Shaffer C, LaCroix K, Jacobus K, Knowles M, Bennett W, et al Uridine 50-triphosphate (UTP) regulates mucociliary clearance via purinergic receptor activation. Drug Dev Res. 1996;37:185
  82. Olivier KN, Bennett WD, Hohneker KW, Zeman KL, Edwards LJ, Boucher RC, et al. Acute safety and effects on mucociliary clearance of aerosolized uridine 50-triphosphate7amiloride in normal human adults. Am J Respir Crit Care Med. 1996;154:217–223
  83. Yerxa BR, Sabater JR, Davis CW, Stutts MJ, Lang-Furr M, Picher M, et al. Pharmacology of INS37217 [P1-(uridine 50)-P4-(20-deoxycytidine 50)tetraphosphate, tetrasodium salt], a next-generation P2Y2 receptor agonist for the treatment ofcystic fibrosis. J Pharmacol Exp Ther. 2002;302:871–880
  84. Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, et al. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol. 2005;39:339–348
  85. Zeitlin PL, Boyle MP, Guggino WB, Molina L. A phase I trial of intranasal Moli1901 for cystic fibrosis. Chest. 2004;125:143–149
  86. Grasemann H, Stehling F, Brunar H, Widmann R, Laliberte TW, Molina L, et al. Inhalation of Moli1901 in patients with cystic fibrosis. Chest. 2007;131:1461–1466
  87. Konstan MW, Berger M. Infection and inflammation of the lung in cystic fibrosis. In:  Davis PB editors. Cystic fibrosis. New York: Marcel Dekker Inc; 1993;
  88. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DWH. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med. 1995;151:1075–1082
  89. Rosenstein BJ, Eigen H. Risks of alternate day prednisolone in patients with cystic fibrosis. Pediatrics. 1991;87:245–246
  90. van Haren EHJ, Lammers JWJ, Festen J, Heijerman HGM, Groot CAR, van Herwaarden CLA. The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis. Resp Med. 1995;89:209–214
  91. Nikolaizik WH, Schoni M. Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis. J Pediatr. 1996;128:271–274
  92. Balfour-Lynn IM, Klein NJ, Dinwiddie R. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Arch Dis Child. 1997;77:124–130
  93. Dauletbaev N, Viel K, Behr J, Loitsch S, Buhl R, Wagner TO, et al. Effects of short-term inhaled fluticasone on oxidative burst of sputum cells in cystic fibrosis. Eur Respir J. 1999;14:1150–1155
  94. De Boeck K, De Baets F, Malfroot A, Desager K, Mouchet F, Proesmans M. Do inhaled corticosteroids impair long-term growth in prepubertal cystic fibrosis patients?. Eur J Pediatr. 2007;166:23–28
  95. Bisgaard H, Pedersen SS, Nielsen KG, Skov M, Laursen EM, Kronborg G, et al. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 1997;156:1190–1196
  96. Wojtczak HA, Kerby GS, Wagener JS, Copenhaver SC, Gotlin RW, Riches DWH, et al. Beclomethasone diproprionate reduced airway inflammation without adrenal suppression in young children with cystic fibrosis: a pilot study. Pediatr Pulmonol. 2001;32:293–302
  97. Balfour-Lynn IM. Multicenter randomised controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med. 2006;173:1356–1362
  98. Balfour-Lynn IM, Walters S, Dezateux C. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev. 2000;1:Art. No: CD001915
  99. McElvaney NG, Hubbard RC, Birrer P, Chernik MS, Caplan DB, Frank MM, et al. Aerosol α1-antitrypsin treatment for cystic fibrosis. Lancet. 1991;337:392–394
  100. Martin SL, Downey D, Bilton D, Keogan MT, Edgar J, Elborn JS, et al. Safety and efficacy of recombinant alpha1-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol. 2006;41:177–183
  101. Griese M, Latzin P, Kappler M, Weckerie K, Heinzimaier T, Bernhardt T, et al. α1-antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J. 2007;29:240–250
  102. Brennan S. Revisiting α1-antitrypsin therapy in cystic fibrosis: can it still offer promise?. Eur Respir J. 2007;29:229–230
  103. McElvaney NG, Doujaiji B, Moan MJ, Burnham MR, Wu MC, Crystal RG. Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolised to normals and individuals with cystic fibrosis. Am Rev Respir Dis. 1993;148:1056–1060
  104. Vogelmeier C, Gillissen A, Buhl R. Use of secretory leukoprotease inhibitor to augment lung antineutrophil elastase activity. Chest. 1996;110:261S–266S
  105. Eggleston PA, Rosenstein BJ, Stackhouse CM, Alexander MF. Airway hyperreactivity in cystic fibrosis. Chest. 1988;94:360–365
  106. Orenstein DM. Long-term inhaled bronchodilator therapy in cystic fibrosis. Chest. 1991;99:1061
  107. Hordvik NL, Konig P, Morris D, Kreutz C, Barbero GJ. A longitudinal study of bronchodilator responsiveness in cystic fibrosis. Am Rev Respir Dis. 1985;131:889–893
  108. Pattishall EN. Longitudinal response of pulmonary function to bronchodilators in cystic fibrosis. Pediatr Pulmonol. 1990;9:80–85
  109. Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits D, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest. 1991;99:1088–1092
  110. Konig P, Gayer D, Barbero GJ, Shaffer J. Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report. Pediatr Pulmonol. 1995;20:205–214
  111. Konig P, Poehler J, Barbero GJ. A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatr Pulmonol. 1998;25:32–36
  112. Hughes T, Clifton IJ, Peckham DG, Etherington C, Pollard K, Conway SP, et al. A retrospective study to assess the response to nebulised salbutamol during a period of stability in adult patients with cystic fibrosis. J Cyst Fibros. 2006;5(Suppl1):S44
  113. Serisier DJ, Coates AD, Bowler SD. Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest. 2007;131:1181–1187
  114. Dodd JD, Barry SC, Daly LE, Gallagher CG. Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. J Cystic Fibros. 2005;4:101–105
  115. Bargon J, Viel K, Dauletbaev N, Wiewrodt R, Buhl R. Short-term effects of regular salmeterol treatment on adult cystic fibrosis patients. Eur Respir J. 1997;10:2307–2311
  116. Hordvik NL, Sammut PH, Judy CG, Colombo JL. Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis. Pediatr Pulmonol. 2002;34:287–296
  117. Salvatore D, D'Andria M. Effects of salmeterol on arterial oxyhemoglobin saturations in patients with cystic fibrosis. Pediatr Pulmonol. 2002;34:11–15
  118. Halfhide C, Evans HJ, Couriel J. Inhaled bronchodilators for cystic fibrosis. Cochrane Database Syst Rev. 2005;4:CD003428
  119. Zach MS, Oberwaldner B, Forche G, Polgar G. Bronchodilators increase airway instability in cystic fibrosis. Am Rev Respir Dis. 1985;131:537–543
  120. Eber E, Oberwaldner B, Zach M. Airway obstruction and airway wall instability in cystic fibrosis: the isolated and combined effects of theophylline and sympathomimetics. Pediatr Pulmonol. 1988;4:205–212
  121. Hellinckx J, De Boeck K, Demedts M. No paradoxical bronchodilator response with forced oscillation technique in children with cystic fibrosis. Chest. 1998;113:55–59
  122. Finnegan MJ, Hughes DV, Hodson ME. Comparison of nebulised and intravenous terbutaline during exacerbations of pulmonary infection in patients with cystic fibrosis. Eur Respir J. 1992;5:1089–1091
  123. Hordvik NL, Sammut PH, Judy CG, Strizek SJ, Colombo JL. The effects of albuterol on the lung function of hospitalised patients with cystic fibrosis. Am J Respir Crit Care Med. 1996;154:156–160
  124. Hordvik NL, Sammut PH, Judy CG, Colombo JL. Effects of standard and high doses of salmeterol on lung function of hospitalised patients with cystic fibrosis. Pediatr Pulmonol. 1999;27:43–53
  125. Weintraub SJ, Eschenbacher WL. The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest. 1989;95:861–864
  126. Ziebach R, Pietsch-Breitfeld B, Bichler M, Busch A, Riethmuller J, Stern M. Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatr Pulmonol. 2001;31:431–435
  127. Sanchez I, Holbrow J, Chernick V. Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. J Pediatr. 1992;120:486–488
  128. Sanchez I, De Koster J, Holbrow J, Chernick V. The effect of high doses of inhaled salbutamol and ipratropium bromide in patients with stable cystic fibrosis. Chest. 1993;104:842–846
  129. Trissel LA. Handbook on injectable drugs. 14th ed. ASHP; 2006;
  130. Anonymous. Drugdex database: http://www.thomsonhc.com, consulted on 10th December 2007a.
  131. Anonymous. The King guide to parenteral admixtures, Loose leaf version, 2007b.
  132. Imamura Y, Higashiyama Y, Tomono K, Izumikawa K, Yanagihara K, Ohno H, et al. Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane. Antimicrob Agents Chemother. 2005;49:1377–1380
  133. Davis SD, Iannetta A, Wedgwood RJ. Activity of colistin against Pseudomonas aeruginosa. Inhibition by calcium. J Infect Dis. 1971;124:610–612
  134. Kamin W, Schwabe A, Krämer I. Inhalation solutions: which ones are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers. J Cyst Fibros. 2006;5:205–213
  135. Berlinski A, Waldrep JC. Nebulized drug admixtures: effect on aerosol characteristics and albuterol output. J Aerosol Med. 2006;19:484–490
  136. Coates AL, MacNeish CF, Meisner D, Kelemen S, Thibert R, MacDonald J. The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols. Chest. 1997;111:1206–1212
  137. Diot P, Dequin PF, Rivoire B, Gagnadoux F, Faurisson F, Diot E, et al. Aerosols and anti-infectious agents. J Aerosol Med. 2001;14:55–64
  138. Faurisson F, Dessanges JF, Grimfeld A, Beaulieu R, Kitzis MD, Peytavin G, et al. Comparative study of the performance and ergonomics of nebulizers in cystic fibrosis. Rev Mal Respir. 1996;13:155–162
  139. Ilowite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis. 1987;136:1445–1449
  140. Collis GG, Cole CH, Le Souef PN. Dilution of nebulised aerosols by air entrainment in children. Lancet. 1990;336:341–343
  141. Devadason SG, Everard ML, Linto JM, Le Souef PN. Comparison of drug delivery from conventional versus “Venturi” nebulizers. Eur Respir J. 1997;10:2479–2483
  142. Devadason SG, Everard ML, MacEarlan C, Roller C, Summers QA, Swift P, et al. Lung deposition from the Turbuhaler in children with cystic fibrosis. Eur Respir J. 1997;10:2023–2028
  143. Newman SP, Woodman G, Clarke SW. Deposition of carbenicillin aerosols in cystic fibrosis: effects of nebuliser system and breathing pattern. Thorax. 1988;43:318–322
  144. Brand P, Meyer T, Haussermann S, Schulte M, Scheuch G, Bernhard T, et al. Optimum peripheral drug deposition in patients with cystic fibrosis. J Aerosol Med. 2005;18:45–54
  145. Zhou Y, Ahuja A, Irvin CM, Kracko D, McDonald JD, Cheng YS. Evaluation of nebulizer performance under various humidity conditions. J Aerosol Med. 2005;18:283–293
  146. Griese M, Ramakers J, Krasselt A, Starosta V, Van Koningsbruggen S, Fischer R, et al. Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis. Am J Respir Crit Care Med. 2004;169:822–888
  147. Touw DJ, Jacobs FA, Brimicombe RW, Heijerman HG, Bakker W, Breimer DD. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 1997;41:184–187
  148. Dequin PF, Faurisson F, Lemarie E, Delatour F, Marchand S, Valat C, et al. Urinary excretion reflects lung deposition of aminoglycoside aerosols in cystic fibrosis. Eur Respir J. 2001;18:316–322
  149. Asmus MJ, Stewart BA, Milavetz G, Teresi ME, Han SH, et al. Tobramycin as a pharmacologic tracer to compare airway deposition from nebulizers. Pharmacotherapy. 2002;22:557–563
  150. Aswania O, Ritson S, Iqbal SM, Bhatt J, Rigby AS, Everard ML. Intra-subject variability in lung dose in healthy volunteers using five conventional portable inhalers. J Aerosol Med. 2004;17:231–238
  151. Alderson PO, Secker-Walker RH, Stominger DB, Markham J, Hill RL. Pulmonary deposition of aerosols in children with cystic fibrosis. J Pediatr. 1974;84:479–484
  152. Chua HL, Collis GG, Newbury AM, Chan K, Bower GD, Sly PD, et al. The influence of age on aerosol deposition in children with cystic fibrosis. Eur Respir J. 1994;7:2185–2191
  153. Mukhopadhyay S, Staddon GE, Eastman C, Palmer M, Davies ER, Carswell F. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Respir Med. 1994;88:203–211
  154. Diot P, Palmer LB, Smaldone A, DeCelie-Germana J, Grimson R, Smaldone GC. RhDNase I aerosol deposition and related factors in cystic fibrosis. Am J Respir Crit Care Med. 1997;156:1662–1668
  155. Diot P, Gagnadoux F, Martin C, Ellataoui H, Furet Y, Breteau M, et al. Nebulization and anti-Pseudomonas aeruginosa activity of colistin. Eur Respir J. 1997;10:1995–1998
  156. Brown JS, Zeman KL, Bennett WD. Regional deposition of coarse particles and ventilation distribution in healthy subjects and patients with cystic fibrosis. J Aerosol Med. 2001;14:443–454
  157. Vanderbist F, Wery B, Baran D, Van Gansbeke B, Schoutens A, Moes AJ. Deposition of nacystelyn from a dry powder inhaler in healthy volunteers and cystic fibrosis patients. Drug Dev Ind Pharm. 2001;27:205–212
  158. Byrne NM, Keavey PM, Perry JD, Gould FK, Spencer DA. Comparison of lung deposition of colomycin using the HaloLite and the Pari LC Plus nebulisers in patients with cystic fibrosis. Arch Dis Child. 2003;88:715–718
  159. Pilcer G, Goole J, Van Gansbeke B, et al. Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formulations in cystic fibrosis patients. Eur J Pharm Biopharm. 2008;68:413–421
  160. Le Brun PP, de Boer AH, Mannes GP, de Fraiture DM, Brimicombe RW, Touw DJ. Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur J Pharm Biopharm. 2002;54:25–32
  161. Westerman EM, De Boer AH, Le Brun PP, Touw DJ, Roldaan AC, Frijlink HW, et al. Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J Cyst Fibros. 2007;6:284–292
  162. Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety. Pediatr Pulmonol. 2007;42:307–313
  163. Kohler E, Sollich V, Schuster-Wonka R, Huhnerbein J. Lung deposition in cystic fibrosis patients using an ultrasonic or a jet nebulizer. J Aerosol Med. 2003;16:37–46
  164. Kohler E, Sollich V, Schuster-Wonka R, Huhnerbein J, Jorch G. Does wearing a nose clip during inhalation improve lung deposition?. J Aerosol Med. 2004;17:116–122
  165. Le Brun PP, de Boer AH, Gjaltema D, Hagedoorn P, Heijerman HG, Frijlink HW. Inhalation of tobramycin in cystic fibrosis. Part 2: optimization of the tobramycin solution for a jet and an ultrasonic nebulizer. Int J Pharm. 1999;189:215–225
  166. Le Brun PP, Vinks AA, Touw DJ, Hekelaar N, Mannes GP, Brimicombe RW, et al. Can tobramycin inhalation be improved with a jet nebulizer?. Ther Drug Monit. 1999;21:618–624
  167. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest. 2002;122:219–226
  168. Newman SP, Pitcairn GR, Hooper G, Knoch M. Efficient drug delivery to the lungs from a continuously operated open-vent nebulizer and low pressure compressor system. Eur Respir J. 1994;7:1177–1181
  169. Kohler E, Sollich V, Schuster-Wonka R, Jorch G. Lung deposition after electronically breath-controlled inhalation and manually triggered conventional inhalation in cystic fibrosis patients. J Aerosol Med. 2005;18:386–395
  170. Newman SP, Flora M, Hirst PH, Klimowicz M, Schaeffler B, Speirs R, et al. Pharmacoscintigraphy of TOBI® in the Pari LC Plus™ and the Aerodose™ inhaler. J Aerosol Med. 2001;14:388
  171. Coates AL, Green M, Leung K, Louca E, Tservistas M, Chan J, et al. The challenges of quantitative measurement of lung deposition using 99mTc-DTPA from delivery systems with very different delivery times. J Aerosol Med. 2007;20:320–330
  172. Nikander K, Prince I, Coughlin S, Warren S, Taylor G. Lung deposition of 99mTc-DTPA delivered with an adaptive aerosol delivery system. Abstract 3264. In: European Respiratory Society Annual Congress, Stockholm. 2007;
  173. Laube BL, Jashnani R, Dalby RN, Zeitlin PL. Targeting aerosol deposition in patients with cystic fibrosis: effects of alterations in particle size and inspiratory flow rate. Chest. 2000;118:1069–1076
  174. de Boer AH, Hagedoorn P, Frijlink HW. The choice of a compressor for the aerosolisation of tobramycin (TOBI) with the PARI LC PLUS reusable nebuliser. Int J Pharm. 2003;268:59–69
  175. Westerman EM, De Boer AH, Le Brun PP, Touw DJ, Roldaan AC, Frijlink HW, et al. Aerosolization of tobramycin (TOBI®) with the PARI LC PLUS® reusable nebulizer: which compressor to use? Comparison of the CR60® to the PortaNeb® compressor. J Aerosol Med Pulm Drug Deliv. 2008;21:269–280
  176. Phipps PR, Gonda I. Droplets produced by medical nebulizers. Some factors affecting their size and solute concentration. Chest. 1990;97:1327–1332
  177. Ho SL, Kwong WTJ, O'Drowsky L, Coates AL. Evaluation of four breath-enhanced nebulizers for home use. J Aerosol Med. 2001;7:467–475
  178. Leung K, Louca E, Coates AL. Comparison of breath-enhanced to breath-actuated nebulizers for rate, consistency, and efficiency. Chest. 2004;126:1619–1627
  179. Everard ML, Clark AR, Milner AD. Drug delivery from jet nebulisers. Arch Dis Child. 1992;67:586–591
  180. Langford SA, Allen MB. Salbutamol output from two jet nebulizers. Respir Med. 1993;87:99–103
  181. McCallion ON, Taylor KM, Thomas M, Taylor AJ. Nebulization of fluids of different physicochemical properties with air-jet and ultrasonic nebulizers. Pharm Res. 1995;12:1682–1688
  182. McCallion ONM, Taylor KMG, Bridges PA, Thomas M, Taylor AJ. Jet nebulisers for pulmonary drug delivery. Int J Pharm. 1996;130:1–14
  183. Weber A, Morlin G, Cohen M, Williams-Warren J, Ramsey B, Smith A. Effect of nebulizer type and antibiotic concentration on device performance. Pediatr Pulmonol. 1997;23:249–260
  184. O'Riordan TG, Amram JC. Effect of nebulizer configuration on delivery of aerosolized tobramycin. J Aerosol Med. 1997;10:13–23
  185. Touw DJ. Optimization of tobramycin treatment in cystic fibrosis: a pharmacokinetic approach. Thesis Rijksuniversiteit Leiden 1996; (Chapter 10):179–188.
  186. Hess DR. Nebulizers: principles and performance. Respir Care. 2000;45:609–622
  187. Kradjan WA, Lakshminarayan S. Efficiency of air compressor-driven nebulizers. Chest. 1985;87:512–516
  188. Ho SL, Coates AL. Effect of dead volume on the efficiency and the cost to deliver medications in cystic fibrosis with four disposable nebulizers. Can Respir J. 1999;6:253–260
  189. Denyer J, Nikander K, Smith NJ. Adaptive aerosol delivery (AAD®) technology. Expert Opin Drug Deliv. 2004;1:165–176
  190. Li Z, Zhang Y, Wurtz BS et al. Characterization of nebulized liposomal amikacin (Arikace™) as a function of droplet size. J Aerosol Med ahead of print. doi:10.1089/jamp.2008.0686.
  191. Clay MM, Pavia D, Newman SP, Lennard-Jones T, Clarke SW. Assessment of jet nebulisers for lung aerosol therapy. Lancet. 1983;2:592–594
  192. Newman SP, Pellow PG, Clay MM, Clarke SW. Evaluation of jet nebulisers for use with gentamicin solution. Thorax. 1985;40:671–676
  193. Nikander K. Drug delivery systems. J Aerosol Med. 1994;7(Suppl 1):S19–S24
  194. de Boer AH, Hagedoorn P, Westerman EM, Le Brun PP, Heijerman HG, Frijlink HW. Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer) for high powder doses. Eur J Pharm Sci. 2006;28:171–178
  195. Tiddens HA, Geller DE, Challoner P, Speirs RJ, Kesser KC, Overbeek SE, et al. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. J Aerosol Med. 2006;19:456–465
  196. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med. 2005;172:1497–1504
  197. Heyder J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc. 2004;1:315–320
  198. Tonnesen P, Stovring S. Positive expiratory pressure (PEP) as lung physiotherapy in cystic fibrosis: a pilot study. Eur J Respir Dis. 1984;65:419–422
  199. Geller DE, Rosenfeld M, Waltz DA, Wilmott RW. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest. 2003;123:28–36
  200. Eisenberg J, Pepe M, Williams-Warren J, Vasiliev M, Montgomery AB, Smith AL, et al. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group. Chest. 1997;111:955–962
  201. Standaert TA, Morlin GL, Williams-Warren J, Joy P, Pepe MS, Weber A, et al. Effects of repetitive use and cleaning techniques of disposable jet nebulizers on aerosol generation. Chest. 1998;114:577–586
  202. Shah PL, Scott SF, Geddes DM, Conway S, Watson A, Nazir T, et al. An evaluation of two aerosol delivery systems for rhDNase. Eur Respir J. 1997;10:1261–1266
  203. Hess D, Fisher D, Williams P, Pooler S, Kacmarek RM. Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand. Chest. 1996;110:498–505
  204. Coates AL, MacNeish CF, Lands LC, Meisner D, Kelemen S, Vadas EB. A comparison of the availability of tobramycin for inhalation from vented vs unvented nebulizers. Chest. 1998;113:951–956
  205. Reisner C, Katial RK, Bartelson BB, Buchmeir A, Rosenwasser LJ, Nelson HS. Characterization of aerosol output from various nebulizer/compressor combinations. Ann Allergy Asthma Immunol. 2001;86:566–574
  206. Van Erp C, de Boer A, Frijlink E, Heijerman H, Sluyter T, Rottier B. Comparative performance evaluation of PARI eFlow® Rapid and PARI LC® Plus nebulizers before and after 6 months use with tobramycin solution (TOBI®). Pediatr Pulmonol Suppl; 30:342–343.
  207. Dyche T, Prince IR, Nikander K. Use of I-neb® AAD® patient logging system data to identify aerosol treatment issues in patients with cystic fibrosis. In: ATS Conference AJRCCM. 2007;p. A782
  208. Knoch M, Wunderlich E, Geldner S. A nebulizer system for highly reproducible aerosol delivery. J Aerosol Med. 1994;7:229–237
  209. Newnham DM, Lipworth BJ. Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system (“Ventstream”). Thorax. 1994;49:762–770
  210. Committee for medicinal products for human use (CHMP). Guideline on the pharmaceutical quality of inhalation and nasal products. EMEA/CHMP/QWP/49313/2005 Corr, 2006.
  211. Barnes KL, Clifford R, Holgate ST, Murphy D, Comber P, Bell E. Bacterial contamination of home nebuliser. Br Med J (Clin Res Ed). 1987;295:812
  212. Pitchford KC, Corey M, Highsmith AK, Perlman R, Bannatyne R, Gold R, et al. Pseudomonas species contamination of cystic fibrosis patients' home inhalation equipment. J Pediatr. 1987;111:212–216
  213. Hutchinson GR, Parker S, Pryor JA, Duncan-Skingle F, Hoffman PN, Hodson ME, et al. Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis. J Clin Microbiol. 1996;34:584–587
  214. Jakobsson BM, Onnered AB, Hjelte L, Nystrom B. Low bacterial contamination of nebulizers in home treatment of cystic fibrosis patients. J Hosp Infect. 1997;36:201–207
  215. Rosenfeld M. Home nebulizer use among patients with cystic fibrosis. J Pediatr. 1998;132:125–131
  216. Rosenfeld M, Gibson R, McNamara S, Emerson J, McCoyd KS, Shell R. Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. J Pediatr. 2001;139:572–577
  217. Rosenfeld M, Joy P, Nguyen CD, Krzewinski J, Burns JL. Cleaning home nebulizers used by patients with cystic fibrosis: is rinsing with tap water enough?. J Hosp Infect. 2001;49:229–230
  218. Vassal S, Taamma R, Marty N, Sardet A, d'Athis P, Bremont F, et al. Microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis. Am J Infect Control. 2000;28:347–351
  219. Saiman L, Siegel J. Infection control in cystic fibrosis. Clin Microbiol Rev. 2004;17:57–71
  220. Jakobsson B, Hjelte L, Nystrom B. Low level of bacterial contamination of mist tents used in home treatment of cystic fibrosis patients. J Hosp Infect. 2000;44:37–41
  221. Kosorok MR, Jalaluddin M, Farrell PM, Shen G, Colby CE, Laxova A, et al. Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis. Pediatr Pulmonol. 1998;26:81–88
  222. O'Malley CA, VandenBranden SL, Zheng XT, Polito AM, McColley SA. A day in the life of a nebulizer: surveillance for bacterial growth in nebulizer equipment of children with cystic fibrosis in the hospital setting. Respir Care. 2007;52:258–262
  223. Kurtz MJ, Van Zandt K, Burns JL. Comparison study of home catheter cleaning methods. Rehabil Nurs. 1995;20:212–214
  224. Lavallee DJ, Lapierre NM, Henwood PK, Pivik JR, Best M, Springthorpe VS, et al. Catheter cleaning for re-use in intermittent catheterization: new light on an old problem. SCI Nurs. 1995;12:10–12
  225. Tablan OC, Chorba TL, Schidlow DV, White JW, Hardy KA, Gilligan PH, et al. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J Pediatr. 1985;107:382–387
  226. Walsh NM, Casano AA, Manangan LP, Sinkowitz-Cochran RL, Jarvis WR. Risk factors for Burkholderia cepacia complex colonization and infection among patients with cystic fibrosis. J Pediatr. 2002;141:512–517
  227. Bakuridze L, Andrieu V, Dupont C, Dubus JC. Does repeated disinfection of the e-Flow rapid nebulizer affect in vitro performance?. J Cyst Fibros. 2007;6:309–310
  228. Reychler G, Aarab K, Van Ossel C, Gigi J, Simon A, Leal T. In vitro evaluation of efficacy of 5 methods of disinfection on mouthpieces and facemasks contaminated by strains of cystic fibrosis patients. J Cyst Fibros. 2005;4:183–187
  229. Rutala WA, Barbee SL, Aguiar NC, Sobsey MD, Weber DJ. Antimicrobial activity of home disinfectants and natural products against potential human pathogens. Infect Control Hosp Epidemiol. 2000;21:33–38
  230. Chatburn RL, Kallstrom TJ, Bajaksouzian S. A comparison of acetic acid with a quaternary ammonium compound for disinfection of hand-held nebulizers. Respir Care. 1988;33:179–187
  231. Lester MK, Flume PA, Gray SL, Anderson D, Bowman CM. Nebulizer use and maintenance by cystic fibrosis patients: a survey study. Respir Care. 2004;49:1504–1508
  232. Wexler MR, Rhame FS, Blumenthal MN, Cameron SB, Juni BA, Fish LA. Transmission of gram-negative bacilli to asthmatic children via home nebulizers. Ann Allergy. 1991;66:267–271
  233. Pankhurst CL, Philpott-Howard J. The environmental risk factors associated with medical and dental equipment in the transmission of Burkholderia (Pseudomonas) cepacia in cystic fibrosis patients. J Hosp Infect. 1996;32:249–255
  234. Simmons BP, Wong ES. Guideline for prevention of nosocomial pneumonia. Infect Control. 1982;3:327–333
  235. Marshall BG, Wangoo A, Harrison LI, Young DB, Shaw RJ. Tumour necrosis factor-alpha production in human alveolar macrophages: modulation by inhaled corticosteroid. Eur Respir J. 2000;15:764–770
  236. Smaldone GC. Deposition patterns of nebulized drugs: is the pattern important?. J Aerosol Med. 1994;7(Suppl 1):S25–S32
  237. Bennett WD, Smaldone GC. Human variation in the peripheral air-space deposition of inhaled particles. J Appl Physiol. 1987;62:1603–1610
  238. Brand P, Friemel I, Meyer T, Schulz H, Heyder J, Haussinger K. Total deposition of therapeutic particles during spontaneous and controlled inhalations. J Pharm Sci. 2000;89:724–731
  239. Martonen T, Katz I, Cress W. Aerosol deposition as a function of airway disease: cystic fibrosis. Pharm Res. 1995;12:96–102
  240. Mallol J, Rattray S, Walker G, Cook D, Robertson CF. Aerosol deposition in infants with cystic fibrosis. Pediatr Pulmonol. 1996;21:276–281
  241. Clavel A, Boulaméry A, Bosdure E, Luc C, Lanteaume A, Gorincour G, et al. Nebulisers comparison with inhaled tobramycin in young children with cystic fibrosis. J Cyst Fibros. 2007;6:137–143
  242. McKenzie JE, Cruz-Rivera M. Compatibility of budesonide inhalation suspension with four nebulizing solutions. Ann Pharmacother. 2004;38:967–972
  243. Lee TY, Chen CM, Lee CN, Chiang YC, Chen HY. Compatibility and osmolality of inhaled N-acetylcysteine nebulizing solution with fenoterol and ipratropium. Am J Health Syst Pharm. 2005;62:828–833
  244. Kraemer I, Schwabe A, Lichtinghagen R, Kamin W. Physiochemical compatibility of nebulizible drug mixtures containing dornase alfa and ipatropium and/or albuterol. Pharmazie. 2007;62:760–766
  245. Finlay WH, Wong JP. Regional lung deposition of nibulised liposome encapsulated ciproflexacin. Int J Pharm. 1998;167:121–127
  246. MICROMEDEX Healthcare Series. Drugdex Drug Evaluations (2007).
  247. Rau JL. Design principles of liquid nebulization devices currently in use Respir Care 2002;47(11):1257–75.
  248. Tandon R, McPeck M, Smaldone GC. Measuring nebulizer output. Aerosol production vs gravimetric analysis. Chest. 1997 May;111(5):1361–1365
  249. Vecellio None L, Grimbert D, Bordenave J, Benoit G, Furet Y, Fauroux B, et al. Residual gravimetric method to measure nebulizer output. J Aerosol Med 2004 Spring;17(1):63–71.

☆ This meeting, held on April 4 to 6, 2008 in Artimino, Tuscany, Italy, was organized by the European Cystic Fibrosis Society. Supported by AOP Orphan Pharmaceuticals AG, Austria; Aradigm Corporation, USA; Bayer Healthcare, Germany; Boehringer Ingelheim GmbH, Germany; Chiesi Farmaceutici, Italy; Forest Pharmaceuticals Inc., USA; Gilead Sciences, USA; Grünenthal GmbH, Germany; Novartis UK, Profile Pharma Limited/Respironics, UK; Roche, Switzerland.

PII: S1569-1993(09)00035-6

doi: 10.1016/j.jcf.2009.04.005

Journal of Cystic Fibrosis
Volume 8, Issue 5 , Pages 295-315 , September 2009

Article Tools